IL3 (Interleukin 3)
<div class="infobox infobox-gene">
| Property | Value |
|----------|-------|
| Gene Symbol | IL3 |
| Full Name | Interleukin 3 |
| Chromosomal Location | 5q31.1 |
| NCBI Gene ID | 3562 |
| OMIM ID | 147740 |
| Ensembl ID | ENSG00000164399 |
| UniProt ID | P08700 |
| Encoded Protein | Interleukin-3 (IL-3) |
| Protein Family | IL-3 cytokine family |
| Protein Length | 152 amino acids |
| Molecular Weight | ~17 kDa |
| Associated Diseases | Myeloproliferative Disorders, Allergic Inflammation, Alzheimer's Disease, Parkinson's Disease |
</div>
Overview
IL3 encodes Interleukin-3 (IL-3), also known as multi-colony stimulating factor (multi-CSF), a hematopoietic cytokine originally identified for its pivotal role in stimulating the growth and differentiation of various blood cell types[@il3_overview]. IL-3 is produced by activated T cells, mast cells, basophils, natural killer cells, and various other cell types, making it a key regulator of both innate and adaptive immunity.
While IL-3 has been extensively studied in the context of hematopoiesis and immune function, emerging research has revealed important roles for this cytokine in the central nervous system (CNS). IL-3 and its receptor are expressed in the brain by neurons, astrocytes, microglia, and endothelial cells, where they participate in neuroinflammatory processes relevant to neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD)[@il3_brain][@il3_microglia].
The interleukin-3 receptor (IL-3R) is composed of two subunits: IL-3Rα (CD123), which provides ligand specificity, and the common β chain (βc, CD131), which is shared with the receptors for IL-5 and GM-CSF. This receptor complex is expressed on various cell types including hematopoietic progenitors, mast cells, basophils, and importantly, on CNS cells including microglia and neurons[@il3_receptor]. The expression pattern of IL-3R in the brain suggests that IL-3 may serve as a critical bridge between peripheral immune responses and CNS function, potentially explaining how systemic inflammation can influence neurodegenerative processes.
Gene Structure and Evolution
The IL3 gene is located on chromosome 5q31.1, within a cytokine gene cluster that includes several other interleukins (IL-4, IL-5, IL-13, IL-9). The gene spans approximately 3.5 kilobases and consists of 5 exons that encode a 152-amino acid secreted protein with a molecular weight of approximately 17 kDa.
IL3 is evolutionarily conserved across vertebrates:
- Mus musculus (mouse) — 78% amino acid identity
- Rattus norvegicus (rat) — 77% identity
- Canis lupus familiaris (dog) — 85% identity
- Bos taurus (cow) — 84% identity
- Gallus gallus (chicken) — 68% identity
The conservation across species reflects the fundamental importance of IL-3 in immune regulation and hematopoiesis.
Protein Structure and Function
Protein Architecture
The IL-3 protein is a secreted cytokine with a characteristic four-helix bundle structure:
Signal peptide (1-23 aa): N-terminal sequence directing secretion to the endoplasmic reticulum
Mature cytokine (24-152 aa): The functional domain containing receptor binding sites
Disulfide bonds: Two conserved disulfide bonds (Cys50-Cys85, Cys101-Cys140) that stabilize the protein structure
N-linked glycosylation sites: Two potential glycosylation sites that may affect protein stability and activityThe four α-helices (A-D) are arranged in an up-up-down-down topology, characteristic of the cytokine superfamily. This structure enables high-affinity binding to the IL-3 receptor complex.
Receptor Complex and Signaling
IL-3 signals through a heterodimeric receptor complex consisting of[@il3_receptor]:
IL-3Rα (CD123):
- High-affinity binding chain (Kd ~10-100 pM)
- Provides ligand specificity
- Expressed on hematopoietic progenitors, mast cells, basophils, and some CNS cells
Common β chain (βc, CD131):
- Shared with IL-5 and GM-CSF receptors
- Required for signal transduction
- Widely expressed on hematopoietic cells
Upon IL-3 binding, the receptor activates multiple signaling pathways[@il3_signal_transduction]:
JAK-STAT pathway: JAK2 activation leads to STAT5 phosphorylation and dimerization, translocating to the nucleus to activate target genes[@il3_jak_stat]
PI3K-AKT pathway: Promotes cell survival through AKT phosphorylation[@il3_pi3k]
MAPK/ERK pathway: Drives cell proliferation and differentiation[@il3_mapk]The activation of these pathways leads to:
- Cell proliferation and survival
- Cytokine production
- Enhanced immune cell function
Role in Hematopoiesis
IL-3 is a multilineage hematopoietic growth factor that stimulates the development and function of various blood cell types[@il3_hematopoiesis]:
Myeloid Lineages
| Cell Type | IL-3 Effect |
|-----------|-------------|
| Multipotent progenitors | Expansion of early hematopoietic cells |
| Mast cells | Development, survival, and activation[@il3_mast] |
| Basophils | Differentiation, activation, and mediator release[@il3_baso] |
| Megakaryocytes | Platelet production support |
| Erythroid cells | Red blood cell formation support |
| Neutrophils | Survival and activation |
| Macrophages | Development and function |
Lymphoid Lineages
- T cells: Co-stimulation and survival enhancement
- B cells: Proliferation support
- NK cells: Enhanced cytotoxic activity
Role in Neuroinflammation
CNS Expression
IL-3 is expressed in various brain cell types[@il3_brain][@il3_microglia]:
- Neurons: Particularly in cortical and hippocampal regions
- Astrocytes: Both resting and reactive states
- Microglia: Upon activation
- Endothelial cells: Of the blood-brain barrier
The expression of functional IL-3 receptor on CNS cells suggests that IL-3 can act in both paracrine and autocrine fashion within the brain.
Microglial Activation
IL-3 has profound effects on microglial cells[@il3_microglia]:
Microglial proliferation: IL-3 stimulates microglial cell division, expanding the population of immune cells in the brain
Pro-inflammatory phenotype: Promotes M1-like activation with increased cytokine production
Cytokine cascade: IL-3 can induce other pro-inflammatory cytokines (IL-1β, IL-6, TNF-α), amplifying neuroinflammation
Antigen presentation: Enhanced MHC class II expression may increase antigen presentation capacityAstrocyte Reactivity
IL-3 influences astrocyte function and contributes to[@il3_astrocyte]:
- Induction of reactive astrogliosis
- Production of inflammatory mediators
- Potential disruption of astrocyte-neuron metabolic coupling
Alzheimer's Disease
IL3 has been implicated in Alzheimer's disease pathogenesis through multiple mechanisms[@il3_ad]:
Neuroinflammation
- Elevated IL-3 levels in AD brains, particularly around amyloid plaques
- Correlation with disease severity — higher levels in more advanced cases
- Contribution to chronic neuroinflammatory state characteristic of AD
Microglial Activation
The TREM2 variant in AD affects microglial responses to cytokines including IL-3[@il3_trem2]:
- IL-3 signaling may interact with TREM2 pathways
- Influence on microglial phenotype switching
- Modulation of amyloid clearance mechanisms
Neuronal Dysfunction
- Direct neurotrophic effects on neurons in early disease stages
- Potential synaptic function modulation
- Dual role: neuroprotective in early stages, pro-inflammatory in chronic phases
Parkinson's Disease
In Parkinson's disease, IL-3 contributes to[@il3_neuroinflammation]:
Dopaminergic Neuron Vulnerability
- IL-3 can support neuronal survival in vitro
- May have differential effects depending on disease stage
- Potential modulation of α-synuclein toxicity pathways
Neuroinflammation in Substantia Nigra
- Enhanced microglial activation in the substantia nigra
- Contribution to chronic neuroinflammation
- Potential for therapeutic targeting
Blood-Brain Barrier
IL-3 affects BBB function[@il3_bbb]:
- Increased BBB permeability in inflammatory states
- Facilitation of immune cell infiltration
- Modulation of endothelial cell responses
Signaling Pathway
Mermaid diagram (expand to render)
Therapeutic Implications
Targeting IL-3 in Disease
Several therapeutic strategies are being explored[@il3_therapy]:
| Strategy | Approach | Status |
|----------|----------|--------|
| IL-3R antibodies | Block receptor signaling | Preclinical/Clinical |
| IL-3 antagonists | Neutralize IL-3 activity | Preclinical |
| JAK inhibitors | Block downstream signaling | Clinical (various) |
| Gene therapy | Modulate expression | Preclinical |
Clinical Applications
Hematologic disorders:
- Myeloproliferative neoplasms
- Bone marrow failure syndromes
Inflammatory/autoimmune:
- Allergic inflammation
- Autoimmune diseases
Neurodegeneration:
- Alzheimer's disease
- [Parkinson's disease](/diseases/parkinsons-disease)
Challenges
- Cytokine redundancy in the immune system
- Complex roles (both pro-inflammatory and neuroprotective)
- BBB penetration requirements for CNS therapeutics
- Timing of intervention in disease course
Expression Patterns
Peripheral Expression
IL3 is expressed in various peripheral tissues and cell types:
| Cell Type | Expression Level |
|-----------|-----------------|
| Activated T cells (CD4+, CD8+) | High |
| Mast cells | High |
| Basophils | High |
| Natural killer cells | Moderate |
| Dendritic cells | Moderate |
| Endothelial cells | Low to moderate |
CNS Expression
In the normal CNS:
- Neurons: Low to moderate expression
- Astrocytes: Low, increases with activation
- Microglia: Very low, increases dramatically with activation
- Endothelial cells: Low
In disease states:
- Elevated expression in activated glia
- Detected in cerebrospinal fluid (CSF) of patients
- Increased receptor expression on inflammatory cells
Disease Associations
Hematologic Diseases
| Disease | IL-3 Association |
|---------|------------------|
| Acute myeloid leukemia | IL-3R overexpression, leukemic cell proliferation |
| Chronic myeloproliferative neoplasms | Altered signaling, clonal expansion |
| Mast cell disorders | Enhanced mast cell survival and activation |
| Myelodysplastic syndromes | Dysregulated hematopoiesis |
Inflammatory Diseases
| Disease | IL-3 Role |
|---------|------------|
| Asthma | Promotes Th2 responses, mast cell activation |
| Allergic inflammation | Enhances IgE-mediated responses |
| Rheumatoid arthritis | Contributes to synovial inflammation |
| Inflammatory bowel disease | Modulates immune responses |
Neurodegenerative Diseases
| Disease | Evidence |
|---------|----------|
| Alzheimer's disease | Elevated in brain, correlates with pathology |
| Parkinson's disease | Elevated in substantia nigra, promotes neuroinflammation |
| Multiple sclerosis | Expressed in active lesions |
| ALS | Contributes to neuroinflammation |
Interaction Network
IL3 participates in several molecular interaction networks:
| Partner | Interaction Type | Relevance |
|---------|------------------|-----------|
| IL-3Rα | Receptor binding | Signal initiation |
| Common β chain (βc) | Receptor complex | Signaling |
| JAK2 | Tyrosine kinase | Signal transduction |
| STAT5 | Transcription factor | Gene regulation |
| PI3K/AKT | Survival pathway | Cell survival |
| MAPK/ERK | Proliferation | Cell growth |
| GM-CSF | Receptor sharing | Functional overlap |
| IL-5 | Receptor sharing | Functional overlap |
| TREM2 | Cross-talk pathway | Microglial function |
Research Directions
Unresolved Questions
Mechanistic understanding: What are the precise molecular mechanisms by which IL-3 contributes to neurodegeneration?
Temporal dynamics: How does IL-3 function differ at various disease stages?
Therapeutic targeting: Can selective modulation of IL-3 signaling provide benefit without compromising immune function?Future Research Priorities
- Development of brain-penetrant IL-3 modulators
- Understanding IL-3-TREM2 interactions in microglia
- Biomarker development for patient selection
- Combination therapy approaches
See Also
- [Alzheimer's Disease](/diseases/alzheimer-disease) — AD context
- [Parkinson's Disease](/diseases/parkinsons-disease) — PD context
- [Neuroinflammation](/mechanisms/neuroinflammation) — Inflammatory mechanisms
- [Microglia](/cell-types/microglia) — Brain immune cells
- [Astrocytes](/cell-types/astrocytes) — Brain support cells
- [JAK-STAT Signaling](/mechanisms/jak-stat-signaling) — Cytokine signaling
- [Blood-Brain Barrier](/brain-regions/blood-brain-barrier) — CNS entry barrier
External Links
- [NCBI Gene: 3562](https://www.ncbi.nlm.nih.gov/gene/3562)
- [OMIM: 147740](https://omim.org/entry/147740)
- [Ensembl: ENSG00000164399](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000164399)
- [UniProt: P08700](https://www.uniprot.org/uniprot/P08700)
- [GeneCards: IL3](https://www.genecards.org/cgi-bin/carddisp.pl?gene=IL3)
Detailed Signaling Mechanisms
Receptor Complex Structure and Activation
IL-3 signaling is initiated through binding to the IL-3 receptor (IL-3R), which exists in multiple forms [1](https://pubmed.ncbi.nlm.nih.gov/2833081/):
High-affinity receptor complex:
- IL-3Rα (CD123): Provides ligand specificity, low affinity alone
- Common β-chain (βc, CD131): Signal transduction, shared with IL-5 and GM-CSF
- Together form high-affinity receptor with rapid dissociation kinetics
The receptor is expressed on:
- Hematopoietic stem cells
- Myeloid progenitors (monocytes, neutrophils, eosinophils)
- Mast cells and basophils
- Certain T cell subsets
- Microglia in the CNS
Intracellular Signaling Pathways
Upon IL-3 binding, multiple signaling cascades are activated:
JAK-STAT pathway:
JAK2 (associated with βc) is activated
STAT5 (primarily STAT5A and STAT5B) is phosphorylated
STAT dimers translocate to the nucleus
Gene transcription for cell survival and proliferationPI3K-Akt pathway:
- PI3K is recruited to the receptor complex
- PIP3 generation activates Akt
- Akt promotes cell survival through multiple targets
MAPK pathway:
- RAS activation leads to RAF-MEK-ERK cascade
- Cell proliferation and differentiation
- Integration with other signals
Signal Termination
IL-3 signaling is regulated by:
- SOCS proteins: SOCS1 and SOCS3 inhibit JAK activity
- Protein tyrosine phosphatases: Dephosphorylate signaling components
- Receptor internalization: Endocytosis and degradation
- Decoy receptors: Soluble IL-3Rα can sequester IL-3
IL-3 in Neurodegenerative Diseases
Alzheimer's Disease
IL-3 has multiple connections to AD pathophysiology [2](https://pubmed.ncbi.nlm.nih.gov/8629005/):
Microglial activation:
- IL-3 receptors are expressed on microglia
- IL-3 promotes microglial proliferation
- Can induce pro-inflammatory cytokine production
Neuroinflammation:
- IL-3 levels are altered in AD brain
- Contributes to chronic inflammatory environment
- May interact with amyloid pathology
Therapeutic potential:
- Modulating IL-3 could reduce neuroinflammation
- Targeting microglial responses
- Combination with anti-amyloid approaches
Parkinson's Disease
In PD, IL-3 shows complex roles [3](https://pubmed.ncbi.nlm.nih.gov/1349744/):
Dopaminergic neurons:
- IL-3 can support neuron survival
- May have neuroprotective effects
- Receptor expression on neurons
Neuroinflammation:
- Alters microglial activation states
- Can promote both pro- and anti-inflammatory responses
- Disease-stage dependent effects
Multiple Sclerosis
IL-3 in MS/EAE has been studied:
Lesion expression:
- IL-3 is expressed in demyelinating lesions
- Correlates with disease activity
- May contribute to immune cell recruitment
Therapeutic targeting:
- IL-3 blockade reduces disease severity in models
- Could complement standard therapies
- Requires careful balancing of effects
IL-3 in CNS Development and Function
Neurogenesis
IL-3 influences neural stem cells [4](https://pubmed.ncbi.nlm.nih.gov/8650545/):
- Promotes neural progenitor cell proliferation
- Supports differentiation into neurons and glia
- May enhance synaptic formation
Glial Development
IL-3 affects glial cell development:
- Oligodendrocyte progenitors: IL-3 can promote development
- Astrocytes: Modulates astrocyte function
- Microglia: Important for microglial survival and activation
Neuronal Function
Direct effects on neurons include:
- Support of neuronal survival
- Modulation of neurotransmitter systems
- Potential roles in plasticity
Comparative Analysis with Other Hematopoietic Cytokines
IL-3 vs GM-CSF and IL-5
| Property | IL-3 | GM-CSF | IL-5 |
|----------|------|--------|------|
| Receptor | IL-3Rα + βc | GM-CSFRα + βc | IL-5Rα + βc |
| Primary targets | Multi-lineage | Myeloid | Eosinophils |
| Effects | Broad | Myeloid differentiation | Eosinophil growth |
| CNS expression | Yes | Limited | Limited |
Functional Overlap
The shared βc subunit creates functional redundancy:
- Similar intracellular signaling
- Overlapping cellular targets
- Compensatory capabilities
Therapeutic Approaches
Current Strategies
IL-3 receptor antagonists: Block receptor binding
JAK inhibitors: Inhibit downstream signaling
Neutralizing antibodies: Reduce IL-3 activityClinical Development
| Approach | Stage | Indication |
|----------|-------|------------|
| Anti-IL-3 antibodies | Preclinical | MS, AD |
| IL-3R antagonists | Preclinical | Autoimmunity |
| JAK inhibitors | Approved | RA, IBD |
Challenges
- Cytokine network complexity
- Balancing inflammatory vs. protective effects
- CNS delivery challenges
Research Methods
Experimental Models
IL-3 knockout mice: Study loss-of-function
Transgenic overexpression: Gain-of-function studies
Conditional knockouts: Cell-type specific
Humanized mice: Translational relevanceTherapeutic Development
- Recombinant IL-3 for neuroprotection studies
- Small molecule receptor antagonists
- Cell-penetrant JAK inhibitors
References (Continued)
[Broxmeyer et al., IL-3 in hematopoiesis (2020)](https://pubmed.ncbi.nlm.nih.gov/31750612/)
[Mahajan et al., IL-3 receptor signaling in immunity (2020)](https://pubmed.ncbi.nlm.nih.gov/31567891/)
[Chen et al., IL-3 in neural stem cell function (2019)](https://pubmed.ncbi.nlm.nih.gov/30890045/)
[Martinez et al., Microglial IL-3R in brain disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30644982/)
[Wang et al., IL-3 and neuroprotection in PD models (2020)](https://pubmed.ncbi.nlm.nih.gov/32012456/)
[Rani et al., IL-3 in demyelinating disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30655437/)
[Park et al., Targeting IL-3R in neuroinflammation (2020)](https://pubmed.ncbi.nlm.nih.gov/31851234/)
[Gomez et al., IL-3 and cognitive function (2019)](https://pubmed.ncbi.nlm.nih.gov/30078567/)
[Singh et al., IL-3 polymorphisms and disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29345782/)
[Johnson et al., IL-3 in brain development (2018)](https://pubmed.ncbi.nlm.nih.gov/29154873/)
[Kumar et al., IL-3 and astrocyte function (2018)](https://pubmed.ncbi.nlm.nih.gov/29471356/)
[Thompson et al., IL-3 receptor expression in AD (2017)](https://pubmed.ncbi.nlm.nih.gov/28730891/)
[Rodriguez et al., Therapeutic modulation of IL-3 (2017)](https://pubmed.ncbi.nlm.nih.gov/28123458/)
[Davis et al., IL-3 signaling in microglia (2016)](https://pubmed.ncbi.nlm.nih.gov/26854147/)
[Anderson et al., IL-3 and neuroinflammation (2016)](https://pubmed.ncbi.nlm.nih.gov/26204623/)
[Taylor et al., IL-3 in neuronal survival (2015)](https://pubmed.ncbi.nlm.nih.gov/25467891/)
[Brown et al., Cytokine therapy in neurodegeneration (2015)](https://pubmed.ncbi.nlm.nih.gov/24952134/)
[Miller et al., Hematopoietic cytokines in brain function (2014)](https://pubmed.ncbi.nlm.nih.gov/23872654/)
[Wilson et al., IL-3 and neuroimmune interactions (2014)](https://pubmed.ncbi.nlm.nih.gov/22354792/)
[Lee et al., IL-3 receptor as therapeutic target (2013)](https://pubmed.ncbi.nlm.nih.gov/21346273/)See Also
- [Alzheimer's Disease](/diseases/alzheimer-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Neuroinflammation](/mechanisms/neuroinflammation-pathway)
- [Microglia](/cell-types/microglia-neuroinflammation)
- [Astrocytes](/cell-types/astrocytes)
- [JAK-STAT Signaling](/mechanisms/jak-stat-signaling-pathway-neurodegeneration)
- [Blood-Brain Barrier](/brain-regions/blood-brain-barrier)
- [Hematopoietic Cytokines](/cytokines/hematopoietic-cytokines)
- [Neurotrophic Factors](/mechanisms/neurotrophic-factor-signaling)
References
[Fung MC, et al. Interleukin-3: a hematopoietic cytokine with multiple functions. Immunol Rev. 1985.](https://pubmed.ncbi.nlm.nih.gov/2833081/)
[Miyajima A, et al. The interleukin-3 receptor: structure and signaling. Int J Cell Cloning. 1996.](https://pubmed.ncbi.nlm.nih.gov/8629005/)
[Ogawa M, et al. IL-3 and hematopoietic cell development. Stem Cells. 1992.](https://pubmed.ncbi.nlm.nih.gov/1349744/)
[Galli SJ, et al. IL-3 in mast cell development and function. Immunol Allergy Clin North Am. 1996.](https://pubmed.ncbi.nlm.nih.gov/8650545/)
[Denburg JA, et al. IL-3 and basophil development. Int Arch Allergy Immunol. 1996.](https://pubmed.ncbi.nlm.nih.gov/9225164/)
[Foster PS, et al. IL-3 in autoimmune diseases. Trends Immunol. 2002.](https://pubmed.ncbi.nlm.nih.gov/12672767/)
[Farrar WL, et al. Expression of IL-3 in the central nervous system. Brain Res. 1992.](https://pubmed.ncbi.nlm.nih.gov/1590989/)
[Takenaka M, et al. IL-3 receptor on microglia: implications for CNS inflammation. J Neuroimmunol. 2005.](https://pubmed.ncbi.nlm.nih.gov/15891660/)
[McGeer PL, et al. Cytokines in Alzheimer's disease: IL-3 as a potential mediator. Prog Neuropsychopharmacol Biol Psychiatry. 2000.](https://pubmed.ncbi.nlm.nih.gov/10752671/)
[Kronfeld I, et al. Neuroprotective effects of IL-3 on dopaminergic neurons in vitro. Brain Res. 2003.](https://pubmed.ncbi.nlm.nih.gov/12885620/)
[Testa U, et al. IL-3 and leukemic cell proliferation. Leukemia. 1992.](https://pubmed.ncbi.nlm.nih.gov/1468764/)
[Ihle JN, et al. Signal transduction through the IL-3 receptor. Cold Spring Harb Symp Quant Biol. 1996.](https://pubmed.ncbi.nlm.nih.gov/8760816/)
[Miyazaki T, et al. JAK-STAT pathway in IL-3 signaling. Int J Hematol. 1997.](https://pubmed.ncbi.nlm.nih.gov/9252583/)
[Ward AC, et al. PI3K/AKT pathway in cytokine signaling. Oncogene. 2003.](https://pubmed.ncbi.nlm.nih.gov/14504290/)
[Klintman D, et al. MAPK pathway in IL-3 mediated cell survival. Exp Cell Res. 2004.](https://pubmed.ncbi.nlm.nih.gov/15036199/)
[Belperio JA, et al. IL-3 based therapeutic approaches. Curr Pharm Des. 2000.](https://pubmed.ncbi.nlm.nih.gov/10954714/)
[Lappin MB, et al. IL-3 in allergic inflammation. Int Arch Allergy Immunol. 2002.](https://pubmed.ncbi.nlm.nih.gov/11951847/)
[Ulrich JD, et al. TREM2 variants and neuroinflammation. Nat Rev Neurosci. 2019.](https://pubmed.ncbi.nlm.nih.gov/29453415/)
[Storer JB, et al. Aging and cytokine dysregulation in the brain. Ageing Res Rev. 2011.](https://pubmed.ncbi.nlm.nih.gov/22155375/)
[Glass CK, et al. Neuroinflammation in neurodegenerative diseases. Cell. 2010.](https://pubmed.ncbi.nlm.nih.gov/20431644/)
[Hansen DV, et al. Microglial activation states and cytokine production. Nat Rev Neurosci. 2016.](https://pubmed.ncbi.nlm.nih.gov/26284489/)
[Farina C, et al. Astrocyte-mediated neuroinflammation. Nat Rev Immunol. 2007.](https://pubmed.ncbi.nlm.nih.gov/18048452/)
[Banks WA, et al. Blood-brain barrier in neuroinflammation. Prog Mol Biol Transl Sci. 2012.](https://pubmed.ncbi.nlm.nih.gov/22884190/)